Vitrectomy in proliferative diabetic retinopathy, the last 10 years

Article

Highlighting the evolving trends in surgical technique and the impact on disease management

This report aims to highlight the evolving trends in surgical management of this complex vitreoretinal disorder and provides some insight into current practice and evidence-based medicine. We will also report our own experiences and share 10 year anatomical and visual outcome in patients who underwent 20-gauge (20G) pars plana vitrectomy (PPV) for complications of PDR under the supervision of a single surgeon (THW) at a teaching hospital in south east London, UK.

Vitrectomy surgery

Smaller gauge transconjunctival sutureless vitrectomy offers theoretical advantages of shorter surgical time, less postoperative inflammation, faster visual recovery and improved patient comfort. But these benefits are balanced in complex vitreoretinal adhesion and fibrovascular proliferations - seen in PDR as a result of altered fluidics with reduced flow through the smaller probe as compared to 20G. Advances such as 25G ultra high speed PPV machinery9 that has better fluid dynamic control, high speed cutting rate (5000 cuts per minute) and viscodissection assisted microincision vitrectomy10 offer new options in microincision vitrectomy.

Anatomical and visual results following PPV in complications due to DR with different gauges of vitrectomy instrumentation are comparable. In a retrospective study of 101 eyes by Park et al.11 no beneficial effects on anatomical and visual outcome were seen after direct comparison between 20- and 23-G PPV. However, there were more cases of hypotony in the 23-G PPV group.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.